ASH News Daily - Saturday, December 10, 2011 - (Page B-39)

A commitment to people living with Type 1 Gaucher disease that’s 17 years strong. Introduced in 1994, Cerezyme was the first recombinant human enzyme replacement therapy. Today only Cerezyme has touched the lives of over 5,600 children and adults with Type 1 Gaucher disease.1 www.cerezyme.com Together, we’ve made the difference. Learn more about diagnosis and treatment with Cerezyme, as well as new therapies for Gaucher disease in development. Contact Genzyme Medical Information at 800-745-4447, option 2. term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions: a) anemia; b) thrombocytopenia; c) bone disease; d) hepatomegaly or splenomegaly. Indication: Cerezyme is indicated for long- Important Safety Information: Approximately 15% of patients have developed IgG antibodies, and these patients have a higher risk of hypersensitivity reaction. Therefore periodic monitoring is suggested; caution should be exercised in patients with antibodies or prior symptoms of hypersensitivity. Symptoms suggestive of hypersensitivity occurred in 6.6% of patients, and include anaphylactoid reaction, pruritus, flushing, urticaria, angioedema, chest discomfort, dyspnea, coughing, cyanosis and hypotension. Reactions related to Cerezyme administration have been reported in less than 15% of patients. Each of the following events occurred in less than 2% of the total patient population. Reported adverse events include nausea, abdominal pain, vomiting, diarrhea, rash, fatigue, headache, fever, dizziness, chills, backache, and tachycardia. Adverse events associated with the route of administration include discomfort, pruritus, burning, swelling or sterile abscess at the site of injection. Side effects should be promptly reported to Genzyme Medical Information at 1-800-745-4447, option 2. To learn more, call 1-888-TYPE1GAUCHER (1-888-897-3142), or visit www.cerezyme.com. Please see Full Prescribing Information on following page. 1. Data on file, ICGG Gaucher Registry. Scan to learn more online 087123_Cerezyme_ASH_Ad_Final.indd 1 9/28/11 9:52 AM 

Table of Contents for the Digital Edition of ASH News Daily - Saturday, December 10, 2011

ASH News Daily - Saturday, December 10, 2011

https://www.nxtbookmedia.com